Acute myeloid leukemia (AML) is one of the most common types of leukemia, a cancer of the blood and bone marrow, killing about 11,000 Americans a year.

Shengqing (Stan) Gu, PhD, an assistant professor at the University of Texas MD Anderson Cancer Center, received a 2023 PhRMA Foundation Faculty Starter Grant in Translational Medicine, for his research to enhance the efficacy of cancer immunotherapy for AML patients.

Watch this video to learn about Gu and his research.